310 results on '"Stoddard, A. M."'
Search Results
2. Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation
3. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ
4. Sources of Information Utilized by Active Duty Service Members for Nutritional Supplement Safety and Efficacy
5. Supplementary Table S4 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
6. Supplementary Table S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
7. Supplementary Table S3 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
8. Supplementary Table S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
9. Data from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
10. Supplementary Table S4 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
11. Supplementary Table S3 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
12. Supplementary Fig. S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
13. Supplementary Fig. S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
14. Supplementary Fig. S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
15. Supplementary Table S5 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
16. Supplementary Table S3 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
17. Supplementary Table S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
18. Supplementary Fig. S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
19. Supplementary Table S5 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
20. Supplementary Table S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
21. Supplementary Table S4 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
22. Supplementary Table S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
23. Data from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
24. Brain/Central Nervous System Malignancies
25. Bone Marrow Aspiration and Biopsy
26. Multiple Myeloma
27. Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
28. Data from Breast Cancer Characteristics and Survival among Users versus Nonusers of Raloxifene
29. Data from Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer
30. Data from Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers
31. Data from Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians
32. Data from Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders
33. Data from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
34. Table S1 from Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers
35. Supplemental Table 1 from Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders
36. Supplementary Table from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
37. Supplemental Table 2 from Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders
38. Supplementary Data from Breast Cancer Characteristics and Survival among Users versus Nonusers of Raloxifene
39. Supplementary Table from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
40. Supplementary Table 1 from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
41. Supplemental File 1 from Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer
42. Supplementary Data from Breast Cancer Characteristics and Survival among Users versus Nonusers of Raloxifene
43. Supplementary Data from Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians
44. Data from Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians
45. Data from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
46. Table S2 from Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers
47. Supplementary Table 1 from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
48. Supplemental Table 1 from Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders
49. Data from Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers
50. Supplemental File 1 from Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.